CN103301372A - Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence - Google Patents
Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence Download PDFInfo
- Publication number
- CN103301372A CN103301372A CN2013102693325A CN201310269332A CN103301372A CN 103301372 A CN103301372 A CN 103301372A CN 2013102693325 A CN2013102693325 A CN 2013102693325A CN 201310269332 A CN201310269332 A CN 201310269332A CN 103301372 A CN103301372 A CN 103301372A
- Authority
- CN
- China
- Prior art keywords
- prostate
- preparation
- brown
- parched
- urinary incontinence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of an umbilicus dressing agent for treating post-operation prostate stress urinary incontinence, which aims at solving the problem of treating post-operation prostate stress urinary incontinence. The preparation method is characterized by comprising the steps of: (1) carrying out decompression distillation on cortex erythrinae, fructus aurantii immaturus and radix ephedrae crude powder to extract volatile oil; (2) carrying out decompression decoction on tetrapanaxpapyrifer to obtain filtrate; (3) decocting smallflower bracketplant herb, rhizome of Japanese Galangal, largeflower jasmine flower, coking malt, scorch-fried medicated leaven, kamuning, peach gum, irkutsk anemone rhizome and decoction dregs obtained from the step (1) with water to obtain filtrate for later use; (4) combining the filtrates of the steps (2) and (3), carrying out concentration at reduced pressure to dry extract, and grinding to obtain dry extract powder; and (5) spraying the volatile oil obtained from the step (1) into the dry extract powder obtained from the step (4), evenly mixing, sieving through a 100-mesh sieve, and subpackaging. Proved by clinical experiments, the drug for treating post-operation prostate stress urinary incontinence has the characteristics of good curative effect and higher safety, thus being worth of clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of preparation method that stress incontinence behind the prostate applies the umbilicus agent for the treatment of.
Background technology
Urinary incontinence is after the male prostate operation and the frequent complication that occurs of urinary tract traumatic patient.Such patient when urinating owing to urethral stricture causes dysuria; When urine storage, can not close fully and cause urine independently not flow out from intravesical owing to urethra again.This situation is regardless of time all can be occured with occasion, thereby often makes the patient suffering can't bear.According to statistics, the probability that urinary incontinence occurs after the Benign Prostatic Hypertrophy operation is 0.5%～2.6%, and the probability that urinary incontinence occurs after the patients with prostate cancer operation is 15%～30%.At present, the few and unsatisfactory curative effect of this sick Therapeutic Method.All the time, male's postoperative urinary incontinence is considered to " global problem " in the Urological Field.
Clinically, stress incontinence thinks that this disease is deficiency syndrome more behind the Chinese traditional treatment prostate, and the setting about for the treatment of a little is to tonify Qi of the kidney, and representative prescription such as large complement commonly used fried in shallow oil, Gu Yin fries in shallow oil.But functional has occured in inventor's clinical research discovery blood supply minimizing and urethral mucosa in operation, and then fibrosis even sclerosis have occured, and has formed " freezing urethra ".The mucous membrane of urethra atrophy, gauffer reduces, thereby urethra is followed the string, and can not provide suitable occlusion pressure to form urinary incontinence.Also namely should disease also have the real sexually transmitted disease (STD) reason of mucous membrane of urethra product to occur on the deficiency syndrome basis, support atrophy, these key pathology links of connective tissue arrangement disorder fibrosis so should fully take into account the mucous membrane of urethra mistake.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provide a kind of curative effect certainly and treatment prostate that side effect is little after stress incontinence apply the umbilicus agent.
The technical scheme that the present invention solves its technical problem is: a kind ofly treat that stress incontinence applies the umbilicus agent behind the prostate, it is characterized in that being prepared from by the crude drug of following weight proportion: 10 ~ 30 parts of Cortex erythrinaes, 6 ~ 12 parts of Herba Chlorophyti Laxis, go back 3 ~ 10 parts in bobbin, 6 ~ 12 parts of Alpinia japonica (Thunb.) Miq.s, 3 ~ 10 parts of Flos jasmini, 6 ~ 12 parts of Fructus Aurantii Immaturuss, 6 ~ 12 parts of Fructus Hordei Germinatus (parched to brown)s, 6 ~ 12 parts of Massa Medicata Fermentata (parched to brown), 6 ~ 12 parts of Radix Ephedraes, 1 ~ 5 part of Folium Et Cacumen Murrayae, 3 ~ 10 parts of gumshiraz, 10 ~ 25 parts of Rhizoma Anemones Altaicaes.
Chinese medicine of the present invention can be prepared from by following method:
(1) volatile oil is extracted in Cortex erythrinae, Fructus Aurantii Immaturus, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and mixing for standby use after collecting, the medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill rear filtration, gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Folium Et Cacumen Murrayae, gumshiraz, Rhizoma Anemones Altaicae and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill rear filtration, gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to get dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
The pressure of the distilling under reduced pressure in the above-mentioned steps (1) is 0.1Mpa.
The pressure that decompression in the above-mentioned steps (2) decocts is 0.4Mpa.
The pressure of the concentrating under reduced pressure in the above-mentioned steps (4) is 0.4Mpa.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..Nature and flavor are bitter, and are flat.Return liver, kidney channel.But the merit wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.But merit heat-clearing and toxic substances removing; The dissipating blood stasis hemostasis.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.But merit tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; The wind syndrome of head headache; The weak breath consumption of essence; Early whitening of beard and hair.
Alpinia japonica (Thunb.) Miq. for Zingiberaceae Alpinia plants Alpinia japonica (Thunb.) Miq. Alpinia japonica Miq., is used as medicine with root stock.Nature and flavor are hot, warm.Return lung, spleen, Liver Channel.But the merit dispelling wind and removing obstruction in the collateral, regulating QI to relieve pain.
Flos jasmini is Oleaceae plants Flos jasmini Jasminu, the dry flower of grandiflorum L..The property mildly bitter flavor; Property is put down.Return Liver Channel.But the merit soothing liver-QI for relieving depression, promoting the circulation of QI to relieve pain.
Fructus Aurantii Immaturus is the dry young fruit of rutaceae Citrus aurantium Linn. Citrus aurantium L. and variety or Fructus Citri sinensis Citrus sinensis Osbeck.But merit dispelling the stagnated QI intestinal stasis relieving.Nature and flavor are bitter, hot, sour, temperature.Return spleen, stomach warp.But merit dispelling the stagnated QI removing food stagnancy, the loose painful abdominal mass of reducing phlegm.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. through the drying of germinateing, fry to burnt brown according to the method for frying, cool sieve dedust bits.Nature and flavor are sweet, and are flat.Return spleen, stomach warp.But the merit promote qi circulation digestion promoting, spleen benefiting and stimulating the appetite moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for the medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven that fermentation forms, fry to burnt brown according to frying method.The sweet suffering of nature and flavor, temperature.Enter spleen, stomach warp.But the merit invigorating the spleen and regulating the stomach is in the accent that helps digestion.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, and are flat.GUIXIN, lung meridian.But merit hidroschesis.
Folium Et Cacumen Murrayae is dried leaves and the band leaf twig of rutaceae Folium Et Cacumen Murrayae Murraya exotica L. and Murraya paniculata (L.) Jack. Murraya paniculata (L.) xJack.Hot, little hardship, temperature.Promoting the circulation of QI to relieve pain, promoting blood circulation to remove blood stasis.
Gumshiraz is rosaceous plant peach Prunus persica (L.) Batsch, the resin that flows out on the trunk.Nature and flavor are bitter, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Rhizoma Anemones Altaicae for Ranunculaceae thimbleweed anemone altaica Anemone altaica Mey., is used as medicine with root stock.Nature and flavor are hot, temperature.But the merit causing resuscitation with aromatic drugs reduces phlegm, and calms the nerves.
Composition principle: stress incontinence thinks that this disease is deficiency syndrome more behind the Chinese traditional treatment prostate, and the setting about for the treatment of a little is to tonify Qi of the kidney, and representative prescription such as large complement commonly used fried in shallow oil, Gu Yin fries in shallow oil.But functional has occured in inventor's clinical research discovery blood supply minimizing and urethral mucosa in operation, and then fibrosis even sclerosis have occured, and has formed " freezing urethra ".The mucous membrane of urethra atrophy, gauffer reduces, thereby urethra is followed the string, and can not provide suitable occlusion pressure to form urinary incontinence.Also namely should disease also have the real sexually transmitted disease (STD) reason of mucous membrane of urethra product to occur on the deficiency syndrome basis, support atrophy, these key pathology links of connective tissue arrangement disorder fibrosis so should fully take into account the mucous membrane of urethra mistake.
Compared with prior art, the present invention has following characteristics:
1, prescription is unique, avoids using in a large number the medicines of tonifying Qi of the kidney: get Cortex erythrinae in the side, go back bobbin and be monarch, Cortex erythrinae dosage of putting down in writing in " China's book on Chinese herbal medicine " is: " taking orally: fry in shallow oil soup, 6-12g "; The inventor experimental results show that (10 ~ 30g) can recover by specific promotion urethral wall mucosa middle heavy dose of Cortex erythrinae, and go back bobbin similar smooth muscle dual regulation are arranged, unbalance for the sphincter vesicae shrinkage expansion;
2, characteristic of the present invention also is balance and restriction: record Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbidding ", but postoperative patient is often with the resembling of deficiency of YIN-blood, and use Cortex erythrinae this moment then has its hematozemia of fearing and causes the yin asthenia generating intrinsic heat appearance; Therefore add Herba Chlorophyti Laxi and go back bobbin, also but the training of bobbin merit tonify deficiency is basic, and can prevent that Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and the Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize its cold heated that prevents on the one hand, but on the other hand its merit dissipating blood stasis hemostasis there is out entire merit in blood system, prevent the Cortex erythrinae moving blood of wandering away, also can not affect Cortex erythrinae simultaneously and work orderly effect; 2. the use of Rhizoma Anemones Altaicae is among the we: a causing resuscitation with aromatic drugs and benefaction, and two Yin Yang balancings, with the bitter cold of balance we invasion by pathogenic cold medicine of a cold nature thing, inventor's clinical research finds that Rhizoma Anemones Altaicae activates yang and do not consume the moon in addition, is suitable for postoperative patient and uses; The application characteristic of Rhizoma Anemones Altaicae is in the prescription of the present invention: measure larger (" consumption in the Chinese pharmacopoeia is 1.5-6g), so too disperse for preventing, get again Radix Ephedrae convergence assistant system;
3, the supplementary drug thing is fewer but better: get the Alpinia japonica (Thunb.) Miq. assistant in the side and help Herba Chlorophyti Laxi, it act as giving treatment in accordance with the tendency of pathological change, regulating air activity; Fructus Aurantii Immaturus and Herba Chlorophyti Laxi collocation have detoxifcation, eliminating stagnation effect, for these pathological products of connective tissue arrangement disorder fibrosis; Inventor's clinical research shows: Flos jasmini can be alleviated bladder irritation effectively; Gumshiraz is invigorated blood circulation, and helps medicine to stay in the part, promotes to absorb;
4, inventor's clinical research is found, the solid protection gastric qi helps the process control of stress incontinence drug disease and recovery behind the prostate, so select Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown) spleen benefiting and stimulating the appetite;
5, Folium Et Cacumen Murrayae is the supplementary drug thing, and inventor's experimental study is found, gets low dose of Folium Et Cacumen Murrayae decocting liquid and can improve the mucous membrane of urethra cytoactive that exsomatizes;
6, the thing homogeneous medicine multiple-effect of getting it filled in the side helps to reduce drug kinds and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through the inventor in a large number, and each raw material consumption is for all to have preferably curative effect in the following weight parts scope;
8, go back the fruit that bobbin is the orchid Rhizoma Gastrodiae, comparing with Rhizoma Gastrodiae, go back the Esterified Enzyme isozyme (esterase isoenzyme) that bobbin contains, may be the key of its performance pharmacological action, and inventor's experiment draws, and goes back bobbin Esterified Enzyme isozyme content after decompression decocts higher.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Alpinia japonica (Thunb.) Miq. 10g, Flos jasmini 6g, Fructus Aurantii Immaturus 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Folium Et Cacumen Murrayae 2g, gumshiraz 6g, Rhizoma Anemones Altaicae 20g.
The preparation method of embodiment 1 is: with Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Aurantii Immaturus, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Folium Et Cacumen Murrayae, gumshiraz, Rhizoma Anemones Altaicae mixing and water adding and decoct, get filtrate after 30 minutes, medicinal residues add water continuation decoction and get filtrate after 20 minutes, twice filtrate merges the umbilical part soak, once a day.
Embodiment 2, the crude drug weight proportion: 10 parts of Cortex erythrinaes, 6 parts of Herba Chlorophyti Laxis, go back 3 parts in bobbin, 6 parts of Alpinia japonica (Thunb.) Miq.s, 3 parts of Flos jasmini, 6 parts of Fructus Aurantii Immaturuss, 6 parts of Fructus Hordei Germinatus (parched to brown)s, 6 parts of Massa Medicata Fermentata (parched to brown), 6 parts of Radix Ephedraes, 1 part of Folium Et Cacumen Murrayae, 3 parts of gumshiraz, 10 parts of Rhizoma Anemones Altaicaes.
Embodiment 3, the crude drug weight proportion: 20 parts of Cortex erythrinaes, 10 parts of Herba Chlorophyti Laxis, go back 6 parts in bobbin, 10 parts of Alpinia japonica (Thunb.) Miq.s, 6 parts of Flos jasmini, 10 parts of Fructus Aurantii Immaturuss, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Folium Et Cacumen Murrayae, 6 parts of gumshiraz, 20 parts of Rhizoma Anemones Altaicaes.
Embodiment 4, the crude drug weight proportion: 30 parts of Cortex erythrinaes, 12 parts of Herba Chlorophyti Laxis, go back 10 parts in bobbin, 12 parts of Alpinia japonica (Thunb.) Miq.s, 10 parts of Flos jasmini, 12 parts of Fructus Aurantii Immaturuss, 12 parts of Fructus Hordei Germinatus (parched to brown)s, 12 parts of Massa Medicata Fermentata (parched to brown), 12 parts of Radix Ephedraes, 5 parts of Folium Et Cacumen Murrayae, 10 parts of gumshiraz, 25 parts of Rhizoma Anemones Altaicaes.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) volatile oil is extracted in Cortex erythrinae, Fructus Aurantii Immaturus, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and mixing for standby use after collecting, the medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill rear filtration, gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Folium Et Cacumen Murrayae, gumshiraz, Rhizoma Anemones Altaicae and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill rear filtration, gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to get dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
In the prioritization scheme, the pressure of the distilling under reduced pressure in the described step (1) is 0.1Mpa; The pressure that decompression in the described step (2) decocts is 0.4Mpa; The pressure of the concentrating under reduced pressure in the described step (4) is 0.4Mpa.
Effective combination of said medicine is coordinated mutually, effectively reach the purpose of stress incontinence medicine behind the treatment prostate, and side effect is less.The above results is the clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case is selected: in December, 2011 ~ 2013 are diagnosed as women with stress urinary incontinence 48 examples behind the prostate year June, and eliminating excreting excrement system infects and kidney disease, previously without operation on pelvis history and neuromuscular pathological changes.
1.1.2 autonomous leakage of urine appearred in (when coughing, laugh, removing weight, change position) when 1. the diagnostic criteria of stress incontinence exerted oneself; 2. diaper test: namely allow patient be with diaper, do after the great quantity of water drinking and jog, stair climbing, lift the activity such as weight, check behind 30min, the 60min that diaper is found leakage of urine and moist person is positive.Any one in above-mentioned two is positive, and diagnosable is stress incontinence.
1.1.3 grouping: be divided into soak group 24 example and deposited umbilicus group 24 examples.Compare in age, the state of an illness, the course of disease before two groups of patient treatments, and the difference not statistically significant (P〉0.05), have comparability.
1.2 method.
1.2.1 Therapeutic Method: the soak group is with gained decoct umbilical part soak in the embodiment of the invention 1,3 times/d.Applying the umbilicus group transfers rear umbilical part accent to apply 1 time/d with gained powder vinegar in the embodiment of the invention 3.Be a course for the treatment of February.
1.2.2 observation index: conventional inquiry medical history before and after the medication, and carry out general questionnaire survey scoring, estimate its situation of urinating.
1.2.3 criterion of therapeutical effect: test the card of urinating with the 24h diaper and be recorded as the curative effect judge index.Cure: incontinence disappears, or diaper test＜2g, effectively is urinary incontinence number of times or diaper test minimizing degree〉50%; Invalid is urinary incontinence number of times or diaper test minimizing degree＜50%.
1.2.4 statistical analysis: SPSS 16.0 carries out statistical analysis.Nonparametric statistics is adopted in the ICIQ-SF scoring.Measurement data is checked with t, enumeration data χ
2Check.
2 results.
2.1 treatment front and back urinary incontinence number of times every day relatively: the soak group is 3.9 ± 1.4 before the treatment, and applying the umbilicus group is 4.1 ± 1.6, the soak group is 1.2 ± 0.6 after treating, and applying the umbilicus group is 1.3 ± 0.5, compares before and after the treatment, and two groups have notable difference (P＜0.05).
2.2 clinical efficacy: after 8 weeks of medication, the cure rate of soak group, effective percentage, inefficiency are respectively 33.33%, 41.67%, 25.00%, and total effective rate is 75.00%.Cure rate, effective percentage, the inefficiency of applying the umbilicus group are respectively 33.33%, 37.50%, 29.17%, and total effective rate is 66.67%.
2.3 adverse reaction rate: obvious adverse reaction does not all appear in two groups of patients.
3. conclusion.
The demonstration of this result of study, the stress incontinence total effective rate is 75.00% and 66.67% behind soak group of the present invention and the deposited umbilicus group treatment prostate.Have that untoward reaction is light, the higher advantage of safety.
Claims (4)
1. preparation method for the treatment of stress incontinence drug powder behind the prostate, it is characterized in that, crude drug comprises: Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Aurantii Immaturus, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Folium Et Cacumen Murrayae, gumshiraz, Rhizoma Anemones Altaicae, its preparation method is comprised of following steps:
(1) volatile oil is extracted in Cortex erythrinae, Fructus Aurantii Immaturus, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and mixing for standby use after collecting, the medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill rear filtration, gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Folium Et Cacumen Murrayae, gumshiraz, Rhizoma Anemones Altaicae and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill rear filtration, gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to get dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
2. a kind of preparation method for the treatment of stress incontinence drug powder behind the prostate according to claim 1, it is characterized in that: the pressure of the distilling under reduced pressure in the described step (1) is 0.1Mpa.
3. a kind of preparation method for the treatment of stress incontinence drug powder behind the prostate according to claim 1, it is characterized in that: the pressure that the decompression in the described step (2) decocts is 0.4Mpa.
4. a kind of preparation method for the treatment of stress incontinence drug powder behind the prostate according to claim 1, it is characterized in that: the pressure of the concentrating under reduced pressure in the described step (4) is 0.4Mpa.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310269332.5A CN103301372B (en) | 2013-07-01 | 2013-07-01 | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence |
| CN201510104982.3A CN104758765A (en) | 2013-07-01 | 2013-07-01 | Umbilical region wet-applying agent for treating prostatic postoperation stress incontinence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310269332.5A CN103301372B (en) | 2013-07-01 | 2013-07-01 | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510104982.3A Division CN104758765A (en) | 2013-07-01 | 2013-07-01 | Umbilical region wet-applying agent for treating prostatic postoperation stress incontinence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103301372A true CN103301372A (en) | 2013-09-18 |
| CN103301372B CN103301372B (en) | 2015-02-11 |
Family
ID=49127378
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510104982.3A Pending CN104758765A (en) | 2013-07-01 | 2013-07-01 | Umbilical region wet-applying agent for treating prostatic postoperation stress incontinence |
| CN201310269332.5A Expired - Fee Related CN103301372B (en) | 2013-07-01 | 2013-07-01 | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510104982.3A Pending CN104758765A (en) | 2013-07-01 | 2013-07-01 | Umbilical region wet-applying agent for treating prostatic postoperation stress incontinence |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN104758765A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491133A (en) * | 2014-12-14 | 2015-04-08 | 刘海燕 | Traditional Chinese medicine foot bathing agent for treating urinary bladder spasm after prostate surgery and nursing method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279007A (en) * | 2008-05-17 | 2008-10-08 | 刘淑霞 | Chinese medicine for curing aconuresis |
| CN101804169A (en) * | 2010-05-28 | 2010-08-18 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating urinary incontinence and preparation method thereof |
| CN102614487A (en) * | 2012-04-19 | 2012-08-01 | 田书庭 | Plaster for treatment of prostate and uracratia |
| CN102988702A (en) * | 2012-12-16 | 2013-03-27 | 孟伟伟 | Navel dressing and nursing agent used for treatment after prostatectomy |
-
2013
- 2013-07-01 CN CN201510104982.3A patent/CN104758765A/en active Pending
- 2013-07-01 CN CN201310269332.5A patent/CN103301372B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279007A (en) * | 2008-05-17 | 2008-10-08 | 刘淑霞 | Chinese medicine for curing aconuresis |
| CN101804169A (en) * | 2010-05-28 | 2010-08-18 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating urinary incontinence and preparation method thereof |
| CN102614487A (en) * | 2012-04-19 | 2012-08-01 | 田书庭 | Plaster for treatment of prostate and uracratia |
| CN102988702A (en) * | 2012-12-16 | 2013-03-27 | 孟伟伟 | Navel dressing and nursing agent used for treatment after prostatectomy |
Non-Patent Citations (2)
| Title |
|---|
| 徐玉建等: "徐福松治疗前列腺切除术后小便失禁的经验", 《江苏中医药》, vol. 23, no. 07, 10 August 2002 (2002-08-10), pages 13 * |
| 杨晓军: "中药配合针灸治疗前列腺术后尿失禁100例", 《中国中医急症》, vol. 20, no. 03, 31 March 2011 (2011-03-31), pages 483 - 484 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491133A (en) * | 2014-12-14 | 2015-04-08 | 刘海燕 | Traditional Chinese medicine foot bathing agent for treating urinary bladder spasm after prostate surgery and nursing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104758765A (en) | 2015-07-08 |
| CN103301372B (en) | 2015-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN103520655A (en) | Traditional Chinese medicine composition for treating psoriasis vulgaris and preparation method thereof | |
| CN105560748A (en) | Toxin drawing-out cream and preparation method thereof | |
| CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
| CN103285300B (en) | Medicinal composition for treating stress incontinence | |
| CN104825956A (en) | Medicine for preventing and treating stroke and recovering muscles, bones and joints | |
| CN103341108B (en) | Pharmaceutical composite for treating stress urinary incontinence after prostatectomy | |
| CN103301372B (en) | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence | |
| CN105412621A (en) | Method for preparing pharmaceutical composition for treating hemorrhoids | |
| CN105343578A (en) | Medicine composition for treating haemorrhoids | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN106110218B (en) | A kind of anti-cancer pain pain relieving plaster and preparation method thereof | |
| CN104623532A (en) | Traditional Chinese medicine composition for treating glioma and preparation method thereof | |
| CN103520644B (en) | Traditional Chinese medicine composition used for treating phlegm stagnation type hyperlipidaemia and preparation method of composition | |
| CN103285301B (en) | Method for preparing umbilicus dressing agent for treating stress incontinence | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN103301375B (en) | Preparation method of umbilical sticking agent for treating nocturia of children | |
| CN103301371B (en) | Preparation method of umbilicus dressing agent for treating primary enuresis | |
| CN105998519A (en) | Oral medicine for treating frequent micturition due to pelvic inflammatory disease | |
| CN103301378B (en) | Pharmaceutical composition for treating nocturia of children | |
| CN106166206A (en) | A kind of gynecological inflammation causes the rehabilitation medicine preparation method of frequent micturition | |
| CN104940524A (en) | Medicine for treating leucoderma and preparation method thereof | |
| CN103861017B (en) | Be used for the treatment of Chinese medicine composition of tuberculous pleural effusion and preparation method thereof | |
| CN103316270A (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN103301374A (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150211 Termination date: 20150701 |
|
| EXPY | Termination of patent right or utility model |